Patents by Inventor William Querbes

William Querbes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PAH-modulating compositions and methods
    Patent number: 12544458
    Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating phenylketonuria (PKU) are described.
    Type: Grant
    Filed: October 26, 2023
    Date of Patent: February 10, 2026
    Assignee: Flagship Pioneering Innovations VI, LLC
    Inventors: Robert Charles Altshuler, Anne Helen Bothmer, Daniel Raymond Chee, Cecilia Giovanna Silvia Cotta-Ramusino, Kyusik Kim, Randi Michelle Kotlar, Gregory David McAllister, Ananya Ray, Nathaniel Roquet, Carlos Sanchez, Barrett Ethan Steinberg, William Edward Salomon, Robert James Citorik, William Querbes, Luciano Henrique Apponi, Zhan Wang
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 12492401
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: June 20, 2023
    Date of Patent: December 9, 2025
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: William Querbes, Kevin Fitzgerald, James Butler, Stephanie Williams, Gregory Hinkle, Martin A. Maier
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 12467051
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: October 17, 2023
    Date of Patent: November 11, 2025
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • PCSK9 iRNA compositions and methods of use thereof
    Patent number: 12460206
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: November 4, 2025
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Anna Borodovsky, Kallanthottathil G. Rajeev, Kevin Fitzgerald, Maria Frank-Kamenetsky, William Querbes, Martin A. Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Muthiah Manoharan, Stuart Milstein
  • CFTR-MODULATING COMPOSITIONS AND METHODS
    Publication number: 20250179482
    Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating cystic fibrosis, e.g., in subjects having a mutation resulting in F508del, are described.
    Type: Application
    Filed: February 21, 2025
    Publication date: June 5, 2025
    Inventors: Robert Charles Altshuler, Anne Helen Bothmer, Daniel Raymond Chee, Cecilia Giovanna Silvia Cotta-Ramusino, Kyusik Kim, Randi Michelle Kotlar, Gregory David McAllister, Aamir Mir, Ananya Ray, Nathaniel Roquet, Carlos Sanchez, Barrett Ethan Steinberg, Robert James Citorik, William Edward Salomon, William Querbes, Luciano Henrique Apponi, Zhan Wang
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
    Publication number: 20250122505
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Application
    Filed: April 9, 2024
    Publication date: April 17, 2025
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda
  • CFTR-modulating compositions and methods
    Patent number: 12270029
    Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating cystic fibrosis, e.g., in subjects having a mutation resulting in F508del, are described.
    Type: Grant
    Filed: September 20, 2023
    Date of Patent: April 8, 2025
    Assignee: Flagship Pioneering Innovations VI, LLC
    Inventors: Robert Charles Altshuler, Anne Helen Bothmer, Daniel Raymond Chee, Cecilia Giovanna Silvia Cotta-Ramusino, Kyusik Kim, Randi Michelle Kotlar, Gregory David McAllister, Aamir Mir, Ananya Ray, Nathaniel Roquet, Carlos Sanchez, Barrett Ethan Steinberg, Robert James Citorik, William Edward Salomon, William Querbes, Luciano Henrique Apponi, Zhan Wang
  • COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
    Publication number: 20250064936
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.
    Type: Application
    Filed: February 7, 2024
    Publication date: February 27, 2025
    Inventors: William Querbes, Kevin Fitzgerald, Brian Bettencourt, Abigail Liebow, David V. Erbe
  • APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20250051765
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
    Type: Application
    Filed: April 29, 2024
    Publication date: February 13, 2025
    Inventors: Kevin Fitzgerald, William Querbes, James Butler, Stephanie Williams, Abigail Liebow, Gregory Hinkle, Martin A. Maier, Stuart Milstein, Satyanarayana Kuchimanchi, Muthiah Manoharan
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
    Publication number: 20250034566
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Application
    Filed: April 9, 2024
    Publication date: January 30, 2025
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
    Publication number: 20240254486
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Application
    Filed: November 6, 2023
    Publication date: August 1, 2024
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda
  • HBB-MODULATING COMPOSITIONS AND METHODS
    Publication number: 20240252682
    Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating sickle cell disease (SCD) are described.
    Type: Application
    Filed: February 28, 2024
    Publication date: August 1, 2024
    Inventors: Robert Charles Altshuler, Anne Helen Bothmer, Daniel Raymond Chee, Cecilia Giovanna Silvia Cotta-Ramusino, Kyusik Kim, Randi Michelle Kotlar, Gregory David McAllister, Ananya Ray, Nathaniel Roquet, Carlos Sanchez, Barrett Ethan Steinberg, William Edward Salomon, Robert James Citorik, William Querbes, Luciano Henrique Apponi, Zhan Wang, Yanfang Fu, Daniel Gene Abernathy, Michael Christopher Holmes
  • ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240200075
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Application
    Filed: June 20, 2023
    Publication date: June 20, 2024
    Inventors: William Querbes, Kevin Fitzgerald, James Butler, Stephanie Williams, Gregory Hinkle, Martin A. Maier
  • ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240175030
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Application
    Filed: October 17, 2023
    Publication date: May 30, 2024
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • CFTR-MODULATING COMPOSITIONS AND METHODS
    Publication number: 20240093186
    Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating cystic fibrosis, e.g., in subjects having a mutation resulting in F508del, are described.
    Type: Application
    Filed: September 20, 2023
    Publication date: March 21, 2024
    Inventors: Robert Charles Altshuler, Anne Helen Bothmer, Daniel Raymond Chee, Cecilia Giovanna Silvia Cotta-Ramusino, Kyusik Kim, Randi Michelle Kotlar, Gregory David McAllister, Aamir Mir, Ananya Ray, Nathaniel Roquet, Carlos Sanchez, Barrett Ethan Steinberg, Robert James Citorik, William Edward Salomon, William Querbes, Luciano Henrique Apponi, Zhan Wang
  • PAH-MODULATING COMPOSITIONS AND METHODS
    Publication number: 20240082429
    Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating phenylketonuria (PKU) are described.
    Type: Application
    Filed: October 26, 2023
    Publication date: March 14, 2024
    Inventors: Robert Charles Altshuler, Anne Helen Bothmer, Daniel Raymond Chee, Cecilia Giovanna Silvia Cotta-Ramusino, Kyusik Kim, Randi Michelle Kotlar, Gregory David McAllister, Ananya Ray, Nathaniel Roquet, Carlos Sanchez, Barrett Ethan Steinberg, William Edward Salomon, Robert James Citorik, William Querbes, Luciano Henrique Apponi, Zhan Wang
  • SERPINA-MODULATING COMPOSITIONS AND METHODS
    Publication number: 20240084334
    Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject. Gene modifying systems for treating alpha-1 antitrypsin deficiency (AATD) are described.
    Type: Application
    Filed: September 18, 2023
    Publication date: March 14, 2024
    Inventors: Robert Charles Altshuler, Anne Helen Bothmer, Daniel Raymond Chee, Cecilia Giovanna Silvia Cotta-Ramusino, Kyusik Kim, Randi Michelle Kotlar, Gregory David McAllister, Ananya Ray, Nathaniel Roquet, Carlos Sanchez, Barrett Ethan Steinberg, William Edward Salomon, Robert James Citorik, William Querbes, Luciano Henrique Apponi, Zhan Wang
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 11866709
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: January 9, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 11840692
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: December 12, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 11834662
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: December 5, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya